NCT00100256View on ClinicalTrials.gov

Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

June 20, 2009

Study Completion Date

April 20, 2025

Conditions
Lung NeoplasmsCarcinoma, Non-Small-Cell LungCarcinoma, Small CellNeoplasm Recurrence, Local
Interventions
DRUG

Rhenium (Re 188 P2045, BAY86-5284)

Infusion once only

Trial Locations (2)

21201

RECRUITING

Baltimore

52242

RECRUITING

Iowa City

Sponsors
All Listed Sponsors
lead

Andarix Pharmaceuticals

INDUSTRY

NCT00100256 - Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy | Biotech Hunter | Biotech Hunter